Global Health Limited MEDANTA NIFTY_MIDNSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.medanta.org

Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emergency, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, and dietetics and nutrition, as well as plastic, aesthetic, and reconstructive surgery. It also provides second opinion, lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, and e-ICU services, and health plans checkup. In addition, the company is involved in trading of pharmacy and other medical consumables; and medical and healthcare education activities. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurugram, India.

Market & Price

Market Cap

₹31,950.19 Cr

Current Price

₹1,189.00

High / Low (52W)

₹1,427.20 / ₹961.10

Beta

0.17

Valuation

Stock P/E

57.47

Industry PE

37.60

Forward P/E

36.84

PEG Ratio

Book Value

₹147.47

Price to Book

8.06

P/S

7.24

EV/EBITDA

34.84

Dividend Yield

0.04%

Profitability & Returns

ROCE

15.05%

ROE

15.03%

ROA

8.16%

Profit Margin

12.62%

Op Margin

15.29%

EPS (Latest Qtr)

₹5.35

EPS (TTM)

₹20.69

Balance Sheet & Liquidity

Debt/Equity

0.30

Quick Ratio

2.46

Current Ratio

2.67

Debt

₹1,190.05 Cr

Total Assets

₹5,905.00 Cr

Current Assets

₹1,674.92 Cr

Working Capital

₹1,047.79 Cr

Ownership

Promoter Holding

67.02%

Chg in Prom Hold

FII / Inst Holding

22.12%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹32,023.14 Cr

Total Revenue (TTM)

₹4,410.27 Cr

EBITDA

₹919.10 Cr

Free Cash Flow

₹-214.19 Cr

Operating Cash Flow

₹714.39 Cr

Shares Outstanding

₹26.87 Cr

Gross Margin

52.54%

Payout Ratio

2.42%

Growth (CAGR)

Revenue 5Y

18.02%

Profit 5Y

19.50%

Revenue (YoY)

24.50%

Earnings (YoY)

42.00%

PROS

Compounding revenue at 18.0% over 5 years.
Profit CAGR of 19.5% over 5 years.

CONS

Trading at a high P/E of 57.5.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MEDANTA Global Health Limited NIFTY_MIDNSEPHARMA	1,189.00	57.47	₹31,950.19 Cr	0.04%	15.05%	15.03%	18.02%	19.50%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	931.25 Cr	1,030.84 Cr	1,099.22 Cr	1,121.05 Cr	1,159.05 Cr
Cost of Revenue	-	-	213.62 Cr	239.06 Cr	255.56 Cr	255.66 Cr	246.53 Cr
Gross Profit	-	-	717.63 Cr	791.78 Cr	843.67 Cr	865.39 Cr	912.52 Cr
Operating Expenses	-	-	542.19 Cr	609.90 Cr	662.45 Cr	709.28 Cr	735.27 Cr
Operating Income	-	-	175.44 Cr	181.88 Cr	181.22 Cr	156.11 Cr	177.25 Cr
EBITDA	-	-	197.72 Cr	267.03 Cr	266.65 Cr	202.48 Cr	280.50 Cr
Interest Expense	-	-	15.03 Cr	13.79 Cr	17.11 Cr	21.51 Cr	26.71 Cr
Pretax Income	-	-	133.44 Cr	208.14 Cr	199.81 Cr	119.78 Cr	187.28 Cr
Tax Provision	-	-	32.06 Cr	49.16 Cr	41.41 Cr	24.75 Cr	45.63 Cr
Net Income	-	-	101.40 Cr	159.01 Cr	158.44 Cr	95.02 Cr	143.99 Cr
Diluted EPS	-	-	3.77	5.91	5.89	3.54	5.35

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	2,682.80 Cr	3,240.94 Cr	3,692.34 Cr	4,410.27 Cr
Cost of Revenue	-	625.28 Cr	759.36 Cr	879.67 Cr	996.80 Cr
Gross Profit	-	2,057.52 Cr	2,481.58 Cr	2,812.68 Cr	3,413.47 Cr
Operating Expenses	-	1,558.46 Cr	1,823.32 Cr	2,129.21 Cr	2,716.91 Cr
Operating Income	-	499.06 Cr	658.26 Cr	683.47 Cr	696.56 Cr
EBITDA	-	676.67 Cr	872.37 Cr	906.26 Cr	1,016.67 Cr
Interest Expense	-	77.46 Cr	72.54 Cr	65.26 Cr	79.11 Cr
Pretax Income	-	449.29 Cr	627.10 Cr	647.26 Cr	715.02 Cr
Tax Provision	-	123.21 Cr	149.04 Cr	165.94 Cr	160.95 Cr
Net Income	-	326.08 Cr	478.19 Cr	481.44 Cr	556.46 Cr
Diluted EPS	7.73	12.57	17.80	17.92	-

Compounded Sales Growth

5 Years:	18.02%
1 Year:	24.50%

Compounded Profit Growth

5 Years:	19.50%
1 Year:	42.00%

Stock Price Performance

1 Year:	-0.64%
6 Months:	-4.92%
3 Months:	+1.97%
1 Month:	+4.03%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	4,115.97 Cr	4,304.07 Cr	4,766.23 Cr	5,905.00 Cr
Current Assets	-	1,579.49 Cr	1,508.73 Cr	1,533.12 Cr	1,674.92 Cr
Cash & Equivalents	-	767.24 Cr	424.61 Cr	230.20 Cr	127.33 Cr
Inventory	-	60.37 Cr	66.85 Cr	67.14 Cr	78.98 Cr
Receivables	-	194.20 Cr	215.31 Cr	291.86 Cr	411.19 Cr
Total Liabilities	-	1,687.76 Cr	1,398.48 Cr	1,378.72 Cr	1,920.73 Cr
Current Liabilities	-	572.55 Cr	617.73 Cr	618.82 Cr	627.13 Cr
Long Term Debt	-	737.12 Cr	283.47 Cr	264.10 Cr	601.12 Cr
Total Debt	-	1,121.95 Cr	801.87 Cr	717.73 Cr	1,190.05 Cr
Total Equity	-	2,428.21 Cr	2,905.63 Cr	3,386.41 Cr	3,961.57 Cr
Shares Outstanding	-	26.82 Cr	26.85 Cr	26.86 Cr	26.87 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	644.52 Cr	612.08 Cr	623.76 Cr	714.39 Cr
Investing Cash Flow	-	-342.35 Cr	-440.80 Cr	-720.94 Cr	-1,089.11 Cr
Financing Cash Flow	-	345.64 Cr	-513.92 Cr	-97.23 Cr	271.85 Cr
Capital Expenditure	-	-235.99 Cr	-278.58 Cr	-647.91 Cr	-978.59 Cr
Free Cash Flow	-	408.53 Cr	333.50 Cr	-24.16 Cr	-264.20 Cr
Net Change in Cash	-	647.81 Cr	-342.63 Cr	-194.41 Cr	-102.87 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	76.7%	76.6%	76.2%	77.4%
Operating Margin %	-	18.6%	20.3%	18.5%	15.8%
Net Margin %	-	12.2%	14.8%	13.0%	12.6%
ROE %	-	13.4%	16.5%	14.2%	14.0%
ROCE %	-	14.1%	17.9%	16.5%	13.2%

Shareholding Pattern

Insiders

67.02%

Institutions

22.12%

Public Float

67.08%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MEDANTA

No recent headlines available.

MEDANTA · Healthcare